Patient recruitment for the Triac 2 course with Emigitat in the second quarter is well advanced and recruitment is expected to end as planned in the fourth quarter of 2021.
CEO Nicholas Westerhom writes this in the interim report.
“I am just happy to be free Despite the challenging Covit-19 situation, we continue to enroll patients for follow-up according to plan. Interim results are scheduled to be available by Q4 2022 and are expected to pave the way for regulatory approvals and business start-ups, ”he added.
Triac 2 is an international, open, multi-center study conducted in Europe and North America on children under 30 months of age with MCT8 deficiency.
According to Aladdin, preparations for 2B / 3 study are underway with the CRO selected to carry out the study as planned in the United States, Great Britain and the European Union.
Covit-19 International Distribution It is even more difficult to start a medical course conducted in emergency and intensive care clinics. Depending on how the situation develops, we expect the beginning of the course to take place by the end of the year, ”said Nicholas Westerhom.
For the continued growth of the company’s medical portfolio, a cash level of approximately SEK 207 million was announced as of June 30th. These funds are aimed at financing the development of Emigrate and Aladdin.
“We are pleased to present Emigitade and Allot projects and their development plans. I look forward to informing you about Ejedis’ plans and future development.
Treatment ”, concluded Nicholas Westerhom as CEO.
“Passionate beer ninja. Extreme problem solver. Thinker. Professional web fan. Avid communicator. Hardcore troublemaker.”